A fusion protein for use in the treatment of an immune related disorder, wherein the immune related disorder is selected from multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, uveitis, or Sjogren's syndrome, the fusion protein having a first fusion partner and a second fusion partner, wherein - the first fusion partner comprises a C1ORF32 polypeptide selected from the group consisting of polypeptide comprising a sequence of amino acid residues having at least 95% sequence identity with amino acid residues 21-186 of H19011_1_P8 (SEQ ID NO: 4), corresponding to amino acid sequence depicted in SEQ ID NO: 14, or residues 21-186 of H19011_1_P8_V1 (SEQ ID NO:5), corresponding to amino acid sequence depicted in SEQ ID NO:35, or residues 21-169 of H19011_1_P9 (SEQ ID NO:6), corresponding to amino acid sequence depicted in SEQ ID NO: 15, or residues 21-169 of H19011_1_P9_V1 (SEQ ID NO:34), corresponding to amino acid sequence depicted in SEQ ID NO:36, or residues 1-184 of the sequence H19011_1_P8 (SEQ ID NO:4), corresponding to amino acid sequence depicted in SEQ ID NO:37, or residues 1-184 of the sequence H19011_1_P8_V1 (SEQ ID NO:5), corresponding to amino acid sequence depicted in SEQ ID NO: 19, or residues 1-169 of H19011_1_P9 (SEQ ID NO:6), corresponding to amino acid sequence depicted in SEQ ID NO:28, or residues 1-169 of H19011_1_P9_V1 (SEQ ID NO:34), corresponding to amino acid sequence depicted in SEQ ID NO:30, - the second fusion partner is composed of a heterologous sequence and contains one or more domains of an immunoglobulin heavy chain constant region, and - the fusion partners are fused together directly or indirectly via a peptide linker sequence or a chemical linker, characterized in that the fusion protein induces immune tolerance in individuals with the immune related disorder. - the first fusion partner comprises a C1ORF32 polypeptide selected from the group consisting of polypeptide comprising a sequence of amino acid residues having at least 95% sequence identity with amino acid residues 21-186 of H19011_1_P8 (SEQ ID NO: 4), corresponding to amino acid sequence depicted in SEQ ID NO: 14, or residues 21-186 of H19011_1_P8_V1 (SEQ ID NO:5), corresponding to amino acid sequence depicted in SEQ ID NO:35, or residues 21-169 of H19011_1_P9 (SEQ ID NO:6), corresponding to amino acid sequence depicted in SEQ ID NO: 15, or residues 21-169 of H19011_1_P9_V1 (SEQ ID NO:34), corresponding to amino acid sequence depicted in SEQ ID NO:36, or residues 1-184 of the sequence H19011_1_P8 (SEQ ID NO:4), corresponding to amino acid sequence depicted in SEQ ID NO:37, or residues 1-184 of the sequence H19011_1_P8_V1 (SEQ ID NO:5), corresponding to amino acid sequence depicted in SEQ ID NO: 19, or residues 1-169 of H19011_1_P9 (SEQ ID NO:6), corresponding to amino acid sequence depicted in SEQ ID NO:28, or residues 1-169 of H19011_1_P9_V1 (SEQ ID NO:34), corresponding to amino acid sequence depicted in SEQ ID NO:30, - the second fusion partner is composed of a heterologous sequence and contains one or more domains of an immunoglobulin heavy chain constant region, and - the fusion partners are fused together directly or indirectly via a peptide linker sequence or a chemical linker,